Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4–7. Recent responder subgroup analyses in the phase III ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient-reported 12-item MS Walking Scale in the 43% of patients classified as responders to PR-fampridine, corresponding to a standardized response mean of 1.68. Use of PR-fampridine in clinical practice varies across Europe, depending partly on whether it is reimbursed. A group of European MS experts met in June 2017 to discuss their experience with using PR-fampridine, including their views on the patient population for treatment, assessment of treatment response, re-testing and re-treatment, and stopping criteria. This article summarizes the experts’ opinions on how PR-fampridine can be used in real-world clinical practice to optimize the benefits to people with MS with impaired walking ability.

Prolonged-release fampridine in multiple sclerosis. clinical data and real-world experience. report of an expert meeting / Albrecht, Philipp; Bjørnå, Ingrid Kristine; Brassat, David; Farrell, Rachel; Feys, Peter; Hobart, Jeremy; Hupperts, Raymond; Linnebank, Michael; Magdič, Jožef; Oreja-Guevara, Celia; Pozzilli, Carlo; Salgado, Antonio Vasco; Ziemssen, Tjalf. - In: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. - ISSN 1756-2856. - 11:(2018), pp. 1-8. [10.1177/1756286418803248]

Prolonged-release fampridine in multiple sclerosis. clinical data and real-world experience. report of an expert meeting

Pozzilli, Carlo;
2018

Abstract

Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4–7. Recent responder subgroup analyses in the phase III ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient-reported 12-item MS Walking Scale in the 43% of patients classified as responders to PR-fampridine, corresponding to a standardized response mean of 1.68. Use of PR-fampridine in clinical practice varies across Europe, depending partly on whether it is reimbursed. A group of European MS experts met in June 2017 to discuss their experience with using PR-fampridine, including their views on the patient population for treatment, assessment of treatment response, re-testing and re-treatment, and stopping criteria. This article summarizes the experts’ opinions on how PR-fampridine can be used in real-world clinical practice to optimize the benefits to people with MS with impaired walking ability.
2018
multiple sclerosis; prolonged-release fampridine; real-world experience; treatment response; walking ability; pharmacology; neurology; neurology (clinical)
01 Pubblicazione su rivista::01a Articolo in rivista
Prolonged-release fampridine in multiple sclerosis. clinical data and real-world experience. report of an expert meeting / Albrecht, Philipp; Bjørnå, Ingrid Kristine; Brassat, David; Farrell, Rachel; Feys, Peter; Hobart, Jeremy; Hupperts, Raymond; Linnebank, Michael; Magdič, Jožef; Oreja-Guevara, Celia; Pozzilli, Carlo; Salgado, Antonio Vasco; Ziemssen, Tjalf. - In: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. - ISSN 1756-2856. - 11:(2018), pp. 1-8. [10.1177/1756286418803248]
File allegati a questo prodotto
File Dimensione Formato  
Albrecht_prolonged-release-fampridine_2018.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 448.93 kB
Formato Adobe PDF
448.93 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1225812
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 8
social impact